Ian De Boer, Md, Ms - Glp-1 Receptor Agonists For Patient With Kidney Disease

Ian de Boer, MD, MS - GLP-1 Receptor Agonists for Patient with Kidney Disease

University of Washington Division of Nephrology

Ian de Boer, MD, MS - Continuous Glucose Monitoring in Chronic Kidney Disease

University of Washington Division of Nephrology

DKD treatment update: SGLT2 inhibitors and finerenone | Ian de Boer & Amrit Lamba

Medicine Matters diabetes

Ian De Boer

Ian De Boer | Day 1 | IDEC 2022

Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

GLP-1 Receptor Agonists and Diabetic KidneyDisease: A Call of Attention to Nephrologists

Sociedad Valenciana de Nefrología

Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

Exploring GLP-1 receptor agonists with Dr Bart van der Schueren

European Medicines Agency

The Link Between Antidiabetic Drugs And Kidney Disease

Dr. Ford Brewer

GLP-1 receptor agonists in patients with CKD not on dialysis; beyond cardiorenal protection

ERA - European Renal Association

GLP-1 in kidney transplantation-is it feasible?

ERA - European Renal Association

SGLT2 Inhibitors vs GLP-1 Agonists: A Cardiologist and an Endocrinologist Weigh In

Professor Mansoor Husain - GLP-1 analogues - have the limits been reached? - Summary version

At the Limits - Leading Medical Education

Professor Mansoor Husain - GLP-1 analogues - have the limits been reached? - Full version

At the Limits - Leading Medical Education

Fundamentals of SGLT2i's and GLP-1RA's for CV Risk

American College of Cardiology

KDIGO Diabetes in CKD Guideline Webinar: Looking at the Latest Evidence and Beyond

Using GLP-1 RAs to Individualize Therapy in T2DM

Kidney Disease Protection: The New Wave of GLP-1 Weight Loss Medicines - A Talk with Dr. Rosansky

Dadvice TV - Kidney Health Coach

Management of Diabetes in CKD: When Worlds Collide

Ottawa Nephrology